Edarbi costs around $261 for a 30-day supply without insurance, making it one of the most expensive blood pressure medications in its class. Generic versions of similar drugs like losartan or valsartan cost a fraction of that, often under $15 per month. The high price comes down to a combination of patent protection, no widely available generic alternative, and its positioning as a premium brand-name product.
No Generic Competition Keeps the Price High
The single biggest reason Edarbi is so expensive is the lack of generic competition. While the FDA has approved one abbreviated application for a generic version of azilsartan (Edarbi’s active ingredient), the drug’s final qualifying patent doesn’t expire until March 2028. Until affordable generic versions actually reach pharmacy shelves, Azurity Pharmaceuticals, the privately held company that currently markets Edarbi, has little competitive pressure to lower the price.
Compare this to other drugs in the same class, known as ARBs (angiotensin receptor blockers). Losartan, valsartan, and olmesartan all lost patent protection years ago. Their generics are widely available for $4 to $20 per month at most pharmacies. Edarbi, at roughly $8.70 per tablet, sits in a completely different pricing tier simply because it doesn’t face the same market forces.
Clinical Advantages Are Real but Modest
Edarbi does have clinical data supporting slightly better blood pressure lowering compared to its competitors, which helps justify its premium positioning. In a trial of nearly 1,300 patients, Edarbi at its highest dose lowered 24-hour systolic blood pressure by about 10 mmHg more than the maximum dose of valsartan and nearly 12 mmHg more than the maximum dose of olmesartan. A second trial of similar size confirmed this edge, though the difference over olmesartan was smaller: about 2 mmHg at the higher dose.
Those differences are statistically significant in clinical trials, but in practical terms, a 2 mmHg advantage is small enough that many doctors and insurers don’t consider it worth the price difference. The drug works through the same mechanism as other ARBs, blocking the same receptor that raises blood pressure. It has an estimated bioavailability of 60% and a 12-hour half-life, which is comparable to other once-daily options in the class. Nothing about its pharmacology makes it dramatically different from cheaper alternatives.
Insurance Coverage Is Often Restricted
Because effective generic ARBs exist, most insurance plans place Edarbi on a high formulary tier or require prior authorization before they’ll cover it. Blue Cross Blue Shield of Mississippi, for example, requires prior authorization for Edarbi prescriptions. Many other plans follow a similar approach: your doctor needs to document why a cheaper ARB isn’t appropriate for you before the insurer will approve coverage.
This creates a frustrating cycle. The drug is expensive at retail, and insurance makes it difficult to access at a lower copay. If your plan does cover it, you’re likely paying a specialty-tier copay rather than the generic-tier price you’d pay for losartan or valsartan. Patients on Medicare, Medicaid, VA, or TriCARE face additional barriers because they’re excluded from the manufacturer’s savings programs.
Savings Programs Can Help, With Limits
Azurity Pharmaceuticals offers a copay savings card that can bring the out-of-pocket cost down to as little as $15 for a 30-day supply. This applies only to commercially insured patients, meaning those with private or employer-sponsored insurance. If you’re uninsured or on a government plan, the savings card won’t apply.
For uninsured patients paying the full retail price, the math is stark: Edarbi costs over $3,100 per year. Switching to a generic ARB could save well over $2,900 annually while still effectively controlling blood pressure. Unless your doctor has a specific clinical reason for choosing Edarbi, such as inadequate response to other ARBs, the cost difference is hard to justify for most people.
Why It Stays Expensive
Edarbi’s pricing reflects a common pattern in the U.S. pharmaceutical market. A brand-name drug with patent protection and no generic substitute can command a high price regardless of whether it offers a major clinical advantage. Azurity Pharmaceuticals is a privately held company that specializes in what it calls “overlooked” patient populations, and it positions Edarbi as a premium product within the ARB class. Without generic competitors on the market to drive prices down, there’s no external force compelling a price reduction.
The situation will likely change after 2028, when generic manufacturers can fully enter the market. Until then, the most practical approach is to ask your prescriber whether a less expensive ARB could work equally well for your blood pressure, or to use the manufacturer’s savings card if you have commercial insurance and your doctor specifically recommends Edarbi.